Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Correlations of Plasma Cytokine Levels and Anti-FVIII Antibodies during Immune Tolerance Induction

Johannes Hartmann, MD, Anja Schmidt, PhD, Marko Beilfuss, Diana Stichel, Christine Heller, MD, Dirk Schwabe, MD, Thomas Klingebiel, MD, Nadia P Ewing, MD, Christoph Koenigs, MD PhD

Blood (2018) 132 (Supplement 1): 2471.

https://doi.org/10.1182/blood-2018-99-110588

Published: 2018

Journal Articles

Microenvironmental Links Between TET2/DNMT3A Mutations and Arginase 1 Overexpression in Human MDS/CMML

Alyssa Cull, MSc, Brooke Snetsinger, MSc, David Good, MD, Rena Buckstein, MD, Richard A. Wells, MD DPhil, Michael J. Rauh, MD PhD

Blood (2016) 128 (22): 3164.

https://doi.org/10.1182/blood.V128.22.3164.3164

Published: 2016

Journal Articles

Tet2 Is a Novel Regulator of Murine Macrophage Differentiation and Polarization

Alyssa Cull, MSc, Brooke Snetsinger, MSc, Michael J. Rauh, MD PhD

Blood (2015) 126 (23): 646.

https://doi.org/10.1182/blood.V126.23.646.646

Published: 2015

Journal Articles

Unique Role of mTOR Inhibitor, Everolimus in Inducible Regulatory T Cells

Tokiko Nagamura-Inoue, MD, PhD., Yuki Yamamoto, MT., Seiichiro Kobayashi, MD, PhD, Kazuo Ogami, Kiyoko Izawa, PhD, Miki Yuzawa, MT., Hajime Tsunoda, MD, PhD., Arinobu Tojo, MD, PhD.

Blood (2012) 120 (21): 4349.

https://doi.org/10.1182/blood.V120.21.4349.4349

Published: 2012

Journal Articles

The Significance of mTOR Inhibitor, Everolimus in TGF-β-Induced Regulatory T cells from Cord Blood

Tokiko Nagamura-Inoue, Seiichiro Kobayashi, MD, PhD, Kazuo Ogami, Yuki Yamamoto, Kiyoko Izawa, PhD, Arinobu Tojo, MD, PhD

Blood (2011) 118 (21): 2180.

https://doi.org/10.1182/blood.V118.21.2180.2180

Published: 2011

Journal Articles

Biomarkers In Cell Death of Imatinib-Resistant Ph-Leukemia Cells During Treatment with mTOR Inhibitor, Everolimus

Miho Minami, Yosuke Minami, MD, PhD, Yachiyo Kuwatsuka, MD, Hitoshi Kiyoi, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2010) 116 (21): 3988.

https://doi.org/10.1182/blood.V116.21.3988.3988

Published: 2010

Journal Articles

Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib In Ph-Leukemia Quiescent Cells.

Yachiyo Kuwatsuka, MD, Yosuke Minami, MD, PhD, Miho Minami, Ryohei Tanizaki, Hitoshi Kiyoi, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2010) 116 (21): 1579.

https://doi.org/10.1182/blood.V116.21.1579.1579

Published: 2010

Journal Articles

Nilotinib as Salvage Therapy In Patients with Chronic Graft Versus Host Disease

Louis Terriou, Leonardo Magro, Eva De Berranger, Jean-Pierre Jouet, MD, Ibrahim Yakoub-Agha, MD, PhD

Blood (2010) 116 (21): 2329.

https://doi.org/10.1182/blood.V116.21.2329.2329

Published: 2010

Journal Articles

Enhanced Natural Killer (NK) and NK T Cell Activation, Expansion and Cytokine Protein Production Following Ex-Vivo Engineering (EvE) of Cryopreserved Umbilical Cord Blood (UCB): Potential Role of CB NK and NKT Cells in Adoptive Cellular Immunotherapy (ACI).

Janet Ayello, MS, Prakash Satwani, MD, Carmella van de Ven, MA, Laxmi Baxi, MD, Ronald Wapner, MD, Etan Sugarman, BA, Mitchell S. Cairo, MD

Blood (2007) 110 (11): 1206.

https://doi.org/10.1182/blood.V110.11.1206.1206

Published: 2007

Journal Articles

Enhanced NK Cell Activation, Cytotoxicity and Ex-Vivo Expansion (EvE) of Cryopreserved Cord Blood (CB) Natural Killer (NK) Cells: Potential Role for CB NK Cells in Adoptive Cellular Immunotherapy (ACI).

Janet Ayello, Julia Nemiroff, Prakash Satwani, Carmella van de Ven, Evan Shereck, Whitney Lomerzow, Ronald Wapner, Laxmi Baxi, Mitchell S. Cairo

Blood (2006) 108 (11): 726.

https://doi.org/10.1182/blood.V108.11.726.726

Published: 2006

Journal Articles

Optimal Ex-Vivo Expansion (EvE) of Cord Blood (CB) Natural Killer (NK) Cells, NK Cytotoxicity and NK Receptor (NKR) Expression: Potential for CB Adoptive Cellular Immunotherapy (ACI).

Janet Ayello, Prakash Satwani, MD, Carmella Van de Ven, Elizabeth Roman, MD, Laxmi Baxi, MD, Joanne Kurtzburg, MD, Mitchell S. Cairo, MD

Blood (2005) 106 (11): 34.

https://doi.org/10.1182/blood.V106.11.34.34

Published: 2005

Journal Articles

Lymphoplasmacytic Cells and Mast Cells Are Targets for Imatinib Mesylate (Gleevec, Glivec) in Waldenstrom’s Macroglobulinemia.

Olivier Tournilhac, Daniel Ditzel Santos, Lian Xu, Evdoxia Hatjiharissi, Yu Tsu, Tai, Laurie Catley, Zachary Hunter, Andrew Branagan, Renate Burger, Reshma Shringarpure, Joshua Boyce, Kenneth C. Anderson, Steven P. Treon

Blood (2004) 104 (11): 4929.

https://doi.org/10.1182/blood.V104.11.4929.4929

Published: 2004

Journal Articles

Prolonged Ex Vivo Expansion (7–10 Days) of Cord Blood (CB) Recryopreserved and Rethawed Aliquots with Anti-CD3, IL-2, IL-12 Significantly Expands NKT Cells, NKT KIR Substes and NK Cytotoxicity Compared to Short-Term Expansion: Potential for CB Adoptive Cellular Immunotherapy (ACI).

Janet Ayello, MS, Prakash Satwani, MD, Carmella van de Ven, MA, Elizabeth Roman, MD, Allison O’Neill, Max Shutran, Matthew Greenhawt, MD, Laxmi Baxi, MD, Lynn Simpson, MD, Joanne Kurtzberg, MD, Mitchell S. Cairo, MD

Blood (2004) 104 (11): 2845.

https://doi.org/10.1182/blood.V104.11.2845.2845

Published: 2004

Journal Articles

Eve of an ADAMTS13 breakthrough

Thomas J. Raife

Blood (2003) 102 (9): 3079–3080.

https://doi.org/10.1182/blood-2003-08-2842

Published: 2003

NARROW

Correlations of Plasma Cytokine Levels and Anti-FVIII Antibodies during Immune Tolerance Induction

Microenvironmental Links Between TET2/DNMT3A Mutations and Arginase 1 Overexpression in Human MDS/CMML

Tet2 Is a Novel Regulator of Murine Macrophage Differentiation and Polarization

Unique Role of mTOR Inhibitor, Everolimus in Inducible Regulatory T Cells

The Significance of mTOR Inhibitor, Everolimus in TGF-β-Induced Regulatory T cells from Cord Blood

Biomarkers In Cell Death of Imatinib-Resistant Ph-Leukemia Cells During Treatment with mTOR Inhibitor, Everolimus

Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib In Ph-Leukemia Quiescent Cells.

Nilotinib as Salvage Therapy In Patients with Chronic Graft Versus Host Disease

Enhanced Natural Killer (NK) and NK T Cell Activation, Expansion and Cytokine Protein Production Following Ex-Vivo Engineering (EvE) of Cryopreserved Umbilical Cord Blood (UCB): Potential Role of CB NK and NKT Cells in Adoptive Cellular Immunotherapy (ACI).

Enhanced NK Cell Activation, Cytotoxicity and Ex-Vivo Expansion (EvE) of Cryopreserved Cord Blood (CB) Natural Killer (NK) Cells: Potential Role for CB NK Cells in Adoptive Cellular Immunotherapy (ACI).

Optimal Ex-Vivo Expansion (EvE) of Cord Blood (CB) Natural Killer (NK) Cells, NK Cytotoxicity and NK Receptor (NKR) Expression: Potential for CB Adoptive Cellular Immunotherapy (ACI).

Lymphoplasmacytic Cells and Mast Cells Are Targets for Imatinib Mesylate (Gleevec, Glivec) in Waldenstrom’s Macroglobulinemia.

Prolonged Ex Vivo Expansion (7–10 Days) of Cord Blood (CB) Recryopreserved and Rethawed Aliquots with Anti-CD3, IL-2, IL-12 Significantly Expands NKT Cells, NKT KIR Substes and NK Cytotoxicity Compared to Short-Term Expansion: Potential for CB Adoptive Cellular Immunotherapy (ACI).

Eve of an ADAMTS13 breakthrough

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only